Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 49, Issue 10, 2008, Pages 1995-1998

  Quinn, J P ^a   Mohamedbhai, S ^a   Chipperfield, K ^a   Treacy, M ^b   D'Sa, S ^a   Nathwani, A C ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b CHASE FARM HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; THALIDOMIDE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER RELAPSE; CANCER RESISTANCE; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONFERENCE PAPER; DISEASE DURATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPOTENSION; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; TACHYCARDIA;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; SALVAGE THERAPY; STEROIDS; TREATMENT OUTCOME;

EID: 55049110133     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802340192     Document Type: Conference Paper

References (11)

1. Keating, M. J., Flinn, I. Jain, V. et al. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 99, pp. 3554-3561.
2. Bowen, D. A. Call, T. G. et al. (2007) Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma, 48, pp. 2412-2417.
3. Thornton, P. D. Matutes, E. et al. (2003) High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol, 82, pp. 759-765.
4. Thornton, P. D. Hamblin, M. et al. (1999) High dose methylprednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma, 4, pp. 167-170.
5. Cheson, B. D. Bennett, J. M. et al. (1996) National cancer institute sponsored working group guidelines for chronic lymphocytic leukaemia: revised guidelines for diagnosis and treatment. Blood, 87, pp. 4990-4997.
6. Dungarwalla, M. Evans, S. O. et al. (2008) High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica, 93, pp. 475-476.
7. Keating, M. J., O'Brien, S. Albitar, M. et al. (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol, 23, pp. 4079-4088.
8. Byrd, J. C. Rai, K. et al. (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood, 105, pp. 49-53.
9. Rose, A. L., Smith, B. E. and Maloney, D. G. (2002) Glucocorticoids and rituximab in vitro: Synergistic direct antiproliferative and apoptotic effects. Blood, 100, pp. 1765-1773.
10. Tam, C. S. Otero-Palacios, J. et al. (2008) Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: A study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol, 141, pp. 36-40.
11. Klepfish, A., Schattner, A. Ghoti, H. et al. (2007) Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia. Lancet Oncol, 8, pp. 361-362.